AAAAAA
Results: 26-50/51
Authors:
Connor, TJ
Kelly, JP
McGee, M
Leonard, BE
Citation: Tj. Connor et al., Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1 beta and TNF-alpha secretion following an in vivo lipopolysaccharide challenge, LIFE SCI, 67(13), 2000, pp. 1601-1612
Authors:
Cryan, JF
Harkin, A
Naughton, M
Kelly, JP
Leonard, BE
Citation: Jf. Cryan et al., Characterization of D-fenfluramine-induced hypothermia: evidence for multiple sites of action, EUR J PHARM, 390(3), 2000, pp. 275-285
Authors:
Wrynn, AS
Mac Sweeney, CP
Franconi, F
Lemaire, L
Pouliquen, D
Herlidou, S
Leonard, BE
Gandon, JM
de Certaines, JD
Citation: As. Wrynn et al., An in-vivo magnetic resonance imaging study of the olfactory bulbectomizedrat model of depression, BRAIN RES, 879(1-2), 2000, pp. 193-199
Authors:
Leonard, BE
Citation: Be. Leonard, Visual perseveration: a new side effect of maprotiline - Invited comment, ACT PSYC SC, 101(6), 2000, pp. 477-477
Authors:
Healy, DG
Harkin, A
Cryan, JF
Kelly, JP
Leonard, BE
Citation: Dg. Healy et al., Metyrapone displays antidepressant-like properties in preclinical paradigms, PSYCHOPHAR, 145(3), 1999, pp. 303-308
Authors:
Connor, TJ
Song, C
Leonard, BE
Anisman, H
Merali, Z
Citation: Tj. Connor et al., Stressor-induced alterations in serotonergic activity in an animal model of depression, NEUROREPORT, 10(3), 1999, pp. 523-528
Authors:
Kelly, JP
Leonard, BE
Citation: Jp. Kelly et Be. Leonard, An investigation of the antidepressant properties of lofepramine and its desmethylated metabolites in the forced swim and olfactory bulbectomized ratmodels of depression, EUR NEUROPS, 9(1-2), 1999, pp. 101-105
Authors:
Redmond, AM
Harkin, A
Kelly, JP
Leonard, BE
Citation: Am. Redmond et al., Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity, EUR NEUROPS, 9(1-2), 1999, pp. 165-170
Authors:
Darcy, P
Dredge, K
Kellehir, P
Kelly, JP
Leonard, BE
Chambers, PL
Citation: P. Darcy et al., Acute toxicity profile of maprotiline in the rat, PHARM TOX, 85(6), 1999, pp. 276-281
Authors:
Leonard, BE
Citation: Be. Leonard, Neuropharmacology of antidepressants that modify central noradrenergic andserotonergic function: A short review, HUM PSYCHOP, 14(2), 1999, pp. 75-81
Authors:
Connor, TJ
McNamara, MG
Kelly, JP
Leonard, BE
Citation: Tj. Connor et al., 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) administration produces dose-dependent neurochemical, endocrine and immune changes in the rat, HUM PSYCHOP, 14(2), 1999, pp. 95-104
Authors:
Leonard, BE
Citation: Be. Leonard, Therapeutic applications of benzodiazepine receptor ligands in anxiety, HUM PSYCHOP, 14(2), 1999, pp. 125-135
Authors:
Leonard, BE
Citation: Be. Leonard, Movement disorders and abuse potential of the selective serotonin reuptakeinhibitors, HUM PSYCHOP, 14(1), 1999, pp. 1-6
Authors:
Leonard, BE
Citation: Be. Leonard, New developments in the pharmacological treatment of anxiety, HUM PSYCHOP, 14, 1999, pp. S52-S59
Authors:
Wrynn, AS
Donohoe, N
Leonard, BE
Citation: As. Wrynn et al., A morphological investigation within the anterior cortical nucleus of the amygdala following olfactory bulbectomy, MED SCI RES, 27(8), 1999, pp. 513-515
Authors:
Shen, Y
Connor, TJ
Kelly, JP
Leonard, BE
Citation: Y. Shen et al., Effects of chronic dietary supplementation with omega 3 and omega 6 fatty acid rich oils on lipopolysaccharide-induced behavioural responses and interleukin-1 beta secretion in the rat, MED SCI RES, 27(5), 1999, pp. 291-294
Authors:
Cryan, JF
Kelliher, P
Kelly, JP
Leonard, BE
Citation: Jf. Cryan et al., Comparative effects of serotonergic agonists with varying efficacy at the 5-HT1A receptor on core body temperature: modification by the selective 5-HT1A receptor antagonist WAY 100635, J PSYCHOPH, 13(3), 1999, pp. 278-283
Authors:
Dredge, K
Connor, TJ
Kelly, JP
Leonard, BE
Citation: K. Dredge et al., Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1 beta and tumor necrosis factor-alpha secretion following an in vivo lipopolysaccharide challenge in rats, INT J IMMUN, 21(10), 1999, pp. 663-673
Authors:
Kelly, JP
Nicolau, G
Redmond, A
Leonard, BE
Noble, J
Sverdlov, L
Molinar, R
Kastin, AJ
Ehrensing, RH
Feighner, JP
Citation: Jp. Kelly et al., The effect of treatment with a new antidepressant, INN 00835, on platelet serotonin uptake in depressed patients, J AFFECT D, 55(2-3), 1999, pp. 231-235
Authors:
Cryan, JF
McGrath, C
Leonard, BE
Norman, TR
Citation: Jf. Cryan et al., Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat, PHARM BIO B, 63(2), 1999, pp. 333-338
Authors:
Redmond, AM
Kelly, JP
Leonard, BE
Citation: Am. Redmond et al., The determination of the optimal dose of milnacipran in the olfactory bulbectomized rat model of depression, PHARM BIO B, 62(4), 1999, pp. 619-623
Authors:
Shen, Y
Conner, TJ
Nolan, Y
Kelly, JP
Leonard, BE
Citation: Y. Shen et al., Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat, LIFE SCI, 65(17), 1999, pp. 1773-1786
Authors:
Connor, TJ
Kelliher, P
Harkin, A
Kelly, JP
Leonard, BE
Citation: Tj. Connor et al., Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat, EUR J PHARM, 379(2-3), 1999, pp. 125-133
Authors:
Harkin, A
Kelly, JP
McNamara, M
Connor, TJ
Dredge, K
Redmond, A
Leonard, BE
Citation: A. Harkin et al., Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression, EUR J PHARM, 364(2-3), 1999, pp. 123-132
Authors:
Leonard, BE
Citation: Be. Leonard, Case studies in psychopharmacology: theme of drugs in psychiatry, ACT PSYC SC, 100(1), 1999, pp. 81-81